



# Integrating OIVD's Pre-Submission/Pre-IDE Process into the IVD Product Development Process

Sheri Hall

VP Quality & Regulatory Affairs

BD Biosciences

April 2010

## Regulatory Goals in Product Development

- Our charter as regulatory project leaders and team members is to
  - Develop clear regulatory strategies that guide submission activities
  - Ensure appropriate product classifications
  - Clearly identify FDA regulatory requirements, confirm clinical trial design adequacy, and verify submission content
  - Chart a successful course through the FDA submission process

## Key Success Factors for Regulatory Affairs

### ■ Success is defined as

- Submission content that provides scientific and clinical evidence that the product is safe, effective, substantially equivalent, and fit for the intended use
- Timely and predictable FDA review cycles and decision outcomes
- Availability of new products to physicians, healthcare providers, and patients



## Business Drivers for Early FDA Interaction

### ■ Time to Market

- Desire to provide new/innovative diagnostics for doctors and patients
- Market leadership in key product areas
- Market windows of opportunity

### ■ Cost of Product Development

- Product development cycles are long and expensive
- Inadequate submission content or clinical studies may result in NSE/not approvable decisions, or delays requiring additional data

## Leveraging the FDA Pre-Submission Process

- In creating regulatory strategies, we need to evaluate the need for a Pre-IDE for the new assay/instrument/software
- Are there elements or issues that could cause problems or delays downstream during FDA review?
- Some points to consider ...
  - ☐ Is this a well characterized device for which there is significant history?
  - ☐ Is the FDA clearance/approval history predictable?

## Leveraging the FDA Pre-Submission Process

- ☐ Are there suitable predicate device(s) or would FDA expect a “gold standard” in addition?
- ☐ Are there new guidances for products of this type, or new expectations not yet included in updated guidance?
- ☐ Is the performance characteristic (non-clinical) test plan & data analysis sufficient?
- ☐ Do we need FDA feedback on the clinical studies design, sample numbers, patient population, or statistical analysis methods if the device or plan is unique?

## Leveraging the FDA Pre-Submission Process

- ☐ Are there supplemental data needed should a de novo pathway be agreed upon?
- ☐ Are there bundling concerns that need to be worked prior to the submission?
- ☐ Does FDA foresee public health issues or concerns surrounding this device or type of device?
- ☐ Is the technology particularly complex that FDA should be engaged prior to the submission, outside of the staff college?


## Leveraging the FDA Pre-Submission Process

- If no issues are identified, the regulatory strategies can proceed without a pre-IDE; the FDA interaction will be in the context of the submission
- If these type of questions identify potential issues, the Pre-Submission process should be of value
- The Pre-Submission process now needs to be built into the IVD product development timelines




# Concept Model for IVD Product Development\*

## ■ IVD product phase-gated process



# Concept Model for IVD Product Development\*


## ■ IVD product phase-gated process (in Quality Systems Design Control terms)



\* Derived from product development process models from 5 IVD companies with FDA cleared/approved products


# Regulatory Deliverables by Phase

- Regulatory Affairs engagement is significant all through the product development process




# Timeline Models for IVD Product Development


## ■ Timelines vary by project & complexity



### Instrument/Systems Development Projects



### Reagent Development Projects - Class I & II




### Reagent Development Projects - Class III & Biologics



The critical window for Pre-IDE decision to drive design and performance testing

# Timeline Models for IVD Product Development

## ■ Timelines vary by project & complexity





## Importance of Timeline Efficiency

- A goal of this workshop is to efficiently and effectively use the Pre-submission process to get answers to our questions about performance and clinical protocols, technology concerns, public health issues, supplemental data sets, or concerns about intended use prior to submission
- So, let's hear from FDA on methods to navigate the process most successfully